Aeterna Zentaris (AEZS) Reports Encouraging Data from Perifosine Phase 1

Article Stock Quotes (1) Comments (0)

Aeterna Zentaris Inc. (Nasdaq: AEZS) announced that Phase 1 trial results for its oral PI3K/Akt inhibitor, perifosine, showed the drug's activity against chemo-resistant and radio-resistant neuroblastoma, while allowing good quality of life and sparing vital organs. Neuroblastoma is a type of childhood cancer which usually begins in nerve tissues. Data were presented yesterday by Brian H. Kushner, MD, of the Memorial Sloan-Kettering Cancer Center in New York, during a poster session at the Advances in Neuroblastoma Research Conference which is being held in Toronto, Canada.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Salix Pharma (SLXP) Reports Positive Results From Two Budesonide Foam Phase 3s
• Ford Motor (F) Will Ramp Production, Halves Two-Week Plant Idling
• Boston Scientific (BSX) Reports Positive Results from NG PROMUS, EVOLVE

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?